Indivior Pharmaceuticals Inc logo INDV - Indivior Pharmaceuticals Inc

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 3
HOLD 0
SELL 0
STRONG
SELL 0
| PRICE TARGET: $44.67 DETAILS
HIGH: $50.00
LOW: $36.00
MEDIAN: $48.00
CONSENSUS: $44.67
UPSIDE: 19.02%

Stock News

New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization

New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization

RICHMOND, Va., May 20, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc., (Nasdaq: INDV) today announced findings from two new real-world evidence studies showing that adherence to extended-release buprenorphine, a monthly injectable commercially available as SUBLOCADE®, is associated with lower relapse risk, fewer infection-related complications, and reduced healthcare utilization among people living with opioid use disorder (OUD). “Collectively, these studies highlight the benefits of sustained treatment with monthly injectable buprenorphine, including reduced relapse risk and fewer serious complications that often drive acute care use,” said Christian Heidbreder, Ph.D., Chief Scientific Officer at Indivior. “These findings also emphasize the importance of proactively identifying patients at risk of treatment discontinuation and supporting continued access to evidence‑based medications for opioid use disorder.”

May 20, 2026 05:00 AM • globenewswire.com
Indivior to Participate in Upcoming Investor Conferences

Indivior to Participate in Upcoming Investor Conferences

RICHMOND, Va., May 14, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will participate in the following upcoming investor conferences: 2026 Jefferies Global Healthcare Conference – New York, NY – June 3 rd Joe Ciaffoni, Chief Executive Officer, and Ryan Preblick, Chief Financial Officer, will host 1x1 / group meetings on Wednesday, June 3rd and will also participate in a fireside chat on Wednesday, June 3rd at 11:05 a.m.

May 14, 2026 03:00 AM • globenewswire.com
Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance

Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance

Q1'26 Total Net Revenue of $317 Million, Up 19% YoY Q1'26 Total SUBLOCADE® Net Revenue of $232 Million, Up 32% YoY Q1'26 GAAP Net Income of $89 Million and Q1'26 Non-GAAP Net Income of $123 Million Record Quarterly Adjusted EBITDA of $164 Million in Q1'26, Up 112% YoY Repurchased Approximately Four Million Shares in Q1'26 for $125 Million Conference Call at 8:00 A.M. EDT Today RICHMOND, Va.

Apr 30, 2026 03:00 AM • globenewswire.com
Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder

Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder

A collaboration with Virginia Tech supports recognizing remission as a treatment outcome-capturing symptoms, quality of life, and functional outcomes-beyond abstinence alone Of all MOUD, monthly extended-release buprenorphine (BUP-XR) accounted for the smallest proportion of non-fatal and fatal OD events compared to no treatment.

Apr 24, 2026 07:00 AM • globenewswire.com
Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder

Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder

RICHMOND, Va., April 24, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV), a leader in the treatment of opioid use disorder (OUD), will present one new scientific poster and collaborated with VA Tech on a second poster which will be presented at the American Society of Addiction Medicine (ASAM) Annual Conference, held April 23-26, 2026, in San Diego, California. The data add to the growing body of evidence evaluating extended-release buprenorphine, a monthly injectable commercially available as SUBLOCADE®, in supporting meaningful outcomes for people living with OUD, including overdose-related outcomes and broader indicators associated with recovery.

Apr 24, 2026 07:00 AM • globenewswire.com
Survey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication Misuse

Survey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication Misuse

RICHMOND, Va., April 16, 2026 (GLOBE NEWSWIRE) -- Indivior PLC (Nasdaq: INDV) today announced results from a national survey published in the Journal of Correctional Health Care showing that correctional leaders identify staffing and coordination gaps as key barriers to reducing diversion of medications for opioid use disorder (MOUD) and recognized long-acting injectable (LAI) buprenorphine as a strategy to help mitigate diversion and improve treatment in jail and prison settings.

Apr 16, 2026 10:30 AM • globenewswire.com
Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th

Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th

RICHMOND, Va., April 09, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its first quarter 2026 financial results on Thursday, April 30, 2026, at 7:00 a.m. U.S. EDT. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 8:00 a.m. U.S. EDT.

Apr 09, 2026 03:00 AM • globenewswire.com

Price Targets